Abatacept for Steroid-Refractory Chronic GVHD: Results From a Phase II Clinical Trial

December 11-14, 2021; Atlanta, Georgia
Abatacept achieved an ORR of 49% and sustained reduction in prednisone dosing over time in patients with steroid-refractory chronic GVHD.
Format: Microsoft PowerPoint (.ppt)
File Size: 157 KB
Released: December 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Multidisciplinary commentary on optimal use of HER2-targeted treatment in early and metastatic breast cancer, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Kristi Kay Orbaugh, MSN, NP, AOCNP Danielle Roman, PharmD, BCOP Released: May 10, 2022

Downloadable resource from Clinical Care Options (CCO) to share with patients that covers the basics of hemophilia A and differences between available prophylaxis therapies

Glaivy Batsuli, MD Released: May 9, 2022

GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)

Corey Cutler, MD, MPH, FRCPC Released: May 4, 2022

From Clinical Care Options (CCO), video webinar on recent advances in management of acute and chronic GVHD for physicians, nurses, and pharmacists

Corey Cutler, MD, MPH, FRCPC David Miklos, MD, PhD Robert Zeiser, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: May 4, 2022 Expired: May 3, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings